Last reviewed: June 26, 2026
Last updated: June 26, 2026
Written by:
Jay Hastings,
CEO of PlexusDx
Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.
Medically reviewed by:
Jayden Lee, PharmD, EMBA
Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.
This article is part of the PlexusDx Education Hub — science-backed guidance on GLP-1 medications, metabolic health, and precision weight management.
Not everyone is a candidate for semaglutide-based weight loss therapy, even though GLP-1 receptor agonists have helped millions lose weight. Your individual health status, medication interactions, and medical history determine whether this approach fits your situation. PlexusDx uses a personalized screening process to match patients with the right therapy.
Who Qualifies for Semaglutide Weight Loss Treatment
Semaglutide eligibility typically starts with your body mass index (BMI) and weight-related health conditions. Adults with a BMI of 30 or higher, or a BMI of 27 or higher with at least one weight-related disease like type 2 diabetes, hypertension, or sleep apnea, are generally appropriate candidates. PlexusDx screens for these markers during the intake consultation to ensure the medication matches your clinical profile.
Your age also matters. Semaglutide is approved for adults 18 and older, but dosing and monitoring become especially important for older adults or those with multiple chronic conditions. PlexusDx requires a full medical history review before recommending any GLP-1 therapy, including assessment of kidney and liver function through recent lab work.
Medical Conditions That May Exclude You From Semaglutide
A personal or family history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia syndrome type 2 (MEN 2) is a strict contraindication to semaglutide use. These rare conditions interact with how GLP-1 agonists affect thyroid cells, making the medication unsafe. PlexusDx specifically asks about these conditions during screening because they are permanent disqualifiers.
Inflammatory bowel disease (IBD), including Crohn's disease and ulcerative colitis, requires careful evaluation before starting semaglutide. Some patients with IBD have experienced symptom worsening on GLP-1 drugs, though the mechanism is still being studied. Recent acute pancreatitis, severe kidney disease, or uncontrolled gallbladder disease may also limit suitability. PlexusDx reviews your GI and endocrine history thoroughly before approval.
Medication Interactions and Semaglutide Compatibility
Semaglutide can interact with oral diabetes medications, particularly sulfonylureas and insulin, which increase hypoglycemia risk when combined. If you take insulin or other glucose-lowering drugs, your prescribing provider at PlexusDx will coordinate dose adjustments with your primary care doctor. These interactions are manageable but require active monitoring and communication between your healthcare team.
Certain blood pressure and heart medications may also require adjustment when starting semaglutide, since GLP-1 therapy can lower blood pressure and heart rate in some patients. PlexusDx requests a complete medication list and recent vital signs to assess compatibility. If you take warfarin or other anticoagulants, weight loss itself (not semaglutide directly) can affect drug effectiveness, necessitating INR monitoring.
How PlexusDx Personalizes Your Semaglutide Eligibility
PlexusDx goes beyond simple BMI cutoffs by evaluating your genetic predisposition to weight gain and metabolic response. The Precision Peptide Genetic Test analyzes key variants in the GLP1R, GIPR, FTO, and MC4R genes—markers that influence how your body responds to GLP-1 therapy. This genetic insight helps predict whether semaglutide injection will be effective for you specifically, not just whether it's medically safe.
Your PlexusDx consultation includes a detailed intake form, optional recent lab review, and a medication cross-check to ensure compounded semaglutide starting at $149/month aligns with your health profile. If you qualify, PlexusDx connects you with a licensed compounding pharmacy (503A, never 503B) and provides ongoing support without requiring insurance. This personalized approach means your eligibility decision accounts for your unique genetic and health context, not just population averages.
How Your Genetics Influence GLP-1 Response
Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, GLP1R rs6923761, FTO rs9939609, and MC4R rs17782313 — influence how your body processes these medications, how much weight you lose, and how you tolerate side effects. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights to match each patient to the right medication, dose, and lifestyle protocol for their biology. The PlexusDx Precision Peptide Genetic Test ($99 add-on after your first month of treatment) gives your provider precise insight into your peptide genetic predispositions before the first prescription is written.
Access Personalized GLP-1 Care Through PlexusDx
PlexusDx offers six prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Semaglutide Injection starts at $149/mo. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test for $99 to personalize your protocol from day one.
Frequently Asked Questions
What is the minimum BMI to start semaglutide with PlexusDx?
PlexusDx typically works with patients whose BMI is 30 or higher, or 27 or higher if you have weight-related conditions like diabetes or hypertension. However, BMI alone does not determine eligibility; your full medical history, medications, and health status are reviewed. Contact PlexusDx for a personalized assessment of your specific situation.
Does a family history of thyroid cancer disqualify me from semaglutide?
A family history of medullary thyroid carcinoma (MTC) or MEN 2 syndrome is a contraindication because semaglutide can affect thyroid cells. PlexusDx specifically screens for personal or family history of these rare conditions during intake. If you have this history, alternative weight loss approaches may be safer for your situation.
Can I take semaglutide if I'm on insulin or other diabetes medications?
Yes, but it requires careful coordination. Semaglutide combined with insulin or sulfonylureas increases hypoglycemia risk, so your provider at PlexusDx will work with your primary care doctor to adjust doses appropriately. Regular blood sugar monitoring is essential when combining these medications.
How does PlexusDx's genetic testing affect my eligibility for semaglutide?
The Precision Peptide Genetic Test ($99 add-on after your first month) analyzes variants in GLP1R, GIPR, FTO, and MC4R genes that predict your metabolic response to semaglutide. This test helps PlexusDx confirm you're a strong candidate and optimize your starting dose, but genetic results do not disqualify you—they personalize your pathway.
What if I have inflammatory bowel disease—can I still take semaglutide?
Patients with IBD can sometimes take semaglutide, but it requires close medical supervision because GLP-1 drugs may worsen IBD symptoms in some individuals. PlexusDx reviews your GI history carefully; if you have active or severe IBD, your provider may recommend alternative options or monitoring strategies before starting therapy.
Related Reading
Pricing and availability current as of June 2026. Compounded GLP-1 medications are not FDA-approved drug products; they are prepared by licensed compounding pharmacies under federal compounding regulations. Compounded semaglutide and tirzepatide are not the same as Wegovy, Ozempic, Zepbound, or Mounjaro. This article is for informational purposes only and does not constitute medical advice. Consult a licensed healthcare provider before starting, stopping, or changing any medication.
Return to the PlexusDx Education Hub for more evidence-based resources on GLP-1 therapy, metabolic health, and personalized weight management.
Medical and Editorial Standards
Medical review process: This article was reviewed for medical accuracy, scientific clarity, evidence alignment, and appropriate discussion of genetics, medications, supplements, biomarkers, and health-related claims.
Sources and evidence: PlexusDx educational content is developed using peer-reviewed research, clinical literature, reputable medical references, and, where applicable, public health or regulatory guidance.
Commercial transparency: PlexusDx offers genetic testing, blood biomarker testing, personalized supplement recommendations, and related precision wellness services. Product mentions are intended to help readers understand available options and should not be interpreted as medical advice.
Important disclaimer: PlexusDx educational content is for informational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making decisions about medications, supplements, genetic testing, lab testing, or health-related care.
Share:
Is There a Weight Limit for Ozempic?
Navigating Pain Relief: Can You Take Ibuprofen While on Wegovy?